Barclays Maintains an 'Equalweight' on Becton Dickinson (BDX); Analyst Day Takeaways
Tweet
Share
E-mailGet Alerts BDX Hot Sheet
Price: $192.00 +2.33%
Rating Summary:
13 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
13 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on Becton Dickinson (NYSE: BDX) price target of $79.00.
Barclays analyst says, "BDX's Analyst Day provided an in-depth look into a plethora of product investments, but provided no incremental financial guidance. Management did not address long-term sales guidance, and FY12 outlook remains unchanged. In line with Q4 comments, FY12 ex-FX sales guidance of 2-4% reflects a base business weighed down by price erosion (just above 100 bps) and uncertainties in utilization and research funding, especially in US/EU. Growth coming out of Europe, however, should incrementally improve yoy as one-time effects roll off (shift in purchasing patterns in Pharma Systems, exiting Greece) and areas like France and possibly UK see some stabilization in research funding levels. While US research spend is likely to be constrained, Asia is expected to lead the pack with double-digit growth in FY12."
For an analyst ratings summary and ratings history on Becton Dickinson click here. For more ratings news on Becton Dickinson click here.
Shares of Becton Dickinson closed at $72.61 yesterday.
Barclays analyst says, "BDX's Analyst Day provided an in-depth look into a plethora of product investments, but provided no incremental financial guidance. Management did not address long-term sales guidance, and FY12 outlook remains unchanged. In line with Q4 comments, FY12 ex-FX sales guidance of 2-4% reflects a base business weighed down by price erosion (just above 100 bps) and uncertainties in utilization and research funding, especially in US/EU. Growth coming out of Europe, however, should incrementally improve yoy as one-time effects roll off (shift in purchasing patterns in Pharma Systems, exiting Greece) and areas like France and possibly UK see some stabilization in research funding levels. While US research spend is likely to be constrained, Asia is expected to lead the pack with double-digit growth in FY12."
For an analyst ratings summary and ratings history on Becton Dickinson click here. For more ratings news on Becton Dickinson click here.
Shares of Becton Dickinson closed at $72.61 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
- Goldman Sachs Downgrades AAC Technologies Holdings Inc. (2018:HK) (AACAY) to Neutral
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
